3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA
Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Director Resignation - Mary Fisher Steps Down from Dermata Board
Dermata Therapeutics Dismisses Baker Tilly as Independent Accountant
Dermata Therapeutics Increases Common Stock Offering by $705,000
Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Termination of License Agreement with Villani, Inc. by Dermata Therapeutics
Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Dermata Therapeutics Increases Offering Amount by $1,792,315
Q3
Q2
Q1
FY 2024
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload